XMFWildWeasel

Stephen D. Simpson

XMFWildWeasel’s Activity

Wed Jul 16

NL

Article

XMFWildWeasel published an article 5:00 PM

Should Roche Buy Exelixis?

A successful phase 3 study has started rumors that Roche may bid for Exelixis

Tue Jul 15

NL

Article

XMFWildWeasel published an article 4:05 PM

Can Roche Find Rare Success In Alzheimer's?

Roche is about to release phase 2 data that could redefine its opportunity in this extremely hard-to-treat disease

NL

Article

XMFWildWeasel published an article 4:00 PM

Johnson & Johnson Ups The Dosage

The pharmaceutical business continues to drive nearly all of the growth at this healthcare giant.

Mon Jul 14

NL

Article

XMFWildWeasel published an article 5:01 PM

Can Anything Derail Salix Pharmaceuticals?

Expanded labeling for the sub-q form of Relistor could add $100 million in revenue, but doesn't change the business to a large extent

NL

Article

XMFWildWeasel published an article 2:00 PM

Abbott And Mylan: Winners and Winners?

Abbott and Mylan strike an uncommon bargain for Abbott's European drug business

NL

Article

XMFWildWeasel published an article 2:00 PM

AbbVie and Shire Close, but Not There Yet

Shire and AbbVie seem to have found their price, but other factors could still derail the deal

Sun Jul 13

NL

Article

XMFWildWeasel published an article 2:41 PM

The Truth Behind Obamacare's Job-Killing Tax

The ACA has had less impact on the med-tech industry, for good or ill, than widely expected

Thu Jul 10

NL

Article

XMFWildWeasel published an article 2:00 PM

Is This Huge Market Slowing Down?

Major joint companies aren't seeing a major pickup in demand for hips or knees

Wed Jul 9

NL

Article

XMFWildWeasel published an article 4:37 PM

Fleeing Taxes, Salix Pharmaceuticals Moves to Ireland

Salix joins the gold rush toward tax inversion

Thu Jul 3

NL

Article

XMFWildWeasel published an article 1:42 PM

Obamacare and Medicare Advantage: How WellPoint Could Outperform

WellPoint is definitely improving under the care of new management

Wed Jul 2

NL

Article

XMFWildWeasel published an article 5:57 PM

Roche Holding Ltd Is Betting Billions on This New Blockbuster

Roche's move to pay as much as $2 billion for Seragon is a major vote of confidence for an unproven therapy approach

NL

Article

XMFWildWeasel published an article 9:30 AM

Why Salix Pharmaceuticals' Good Data Wasn't Great

Salix was short on specifics but word of a successful IBS-D study should calm some nervous stomachs among investors

Tue Jul 1

NL

Article

XMFWildWeasel published an article 4:13 PM

Up 8%: Does Cooper Companies Inc's Buyout Make Sense?

Cooper's deal for Sauflon isn't cheap, but adds valuable products and potential growth leverage

NL

Article

XMFWildWeasel published an article 2:01 PM

Time to Buy a Stumbling UnitedHealth Group, Inc?

UnitedHealth had some operational issues earlier this year, but remains a well-run managed care company

Mon Jun 30

NL

Article

XMFWildWeasel published an article 2:01 PM

MannKind Stock: Afrezza Approved at Last, But Will Sales Disappoint?

MannKind finally got its approval for inhaled insulin, but the marketing challenges are only beginning.

Fri Jun 27

NL

Article

XMFWildWeasel published an article 8:30 AM

Auxilium Pharmaceuticals Inc Joins the Buyout Bonanza

Auxilium's acquisition of QLT guarantees dilution but could produce tax benefits down the road if profits improve

Wed Jun 25

NL

Article

XMFWildWeasel published an article 1:01 PM

A Smart Move for Endo International?

Endo International PLC management continues to build value through acquisitions

Tue Jun 24

NL

Article

XMFWildWeasel published an article 1:53 PM

A Big Step Forward for Vertex Pharmaceuticals, Inc

Vertex's phase 3 data on combo therapy for cystic fibrosis were not flawless, but they were good enough to answer the bears

Mon Jun 23

NL

Article

XMFWildWeasel published an article 5:01 PM

Boston's Watchman Under New FDA Scrutiny

BSX's announcement of a third panel meeting for the Watchman device is a small setback, but a setback nonetheless.

Fri Jun 20

NL

Article

XMFWildWeasel published an article 6:23 PM

Who Will Win This $45 Billion Market?

Novo's position in diabetes looks safe, while Lilly has bold plans to be a share-gainer.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 69329
Score 0.00
Score Change Today 0
Accuracy 0.00%
Active Picks 0
Total Picks 0
Best Pick ( 0)
Worst Pick ( 0)
Average Score per Pick 0.00
Charms Earned 0
Highest Rated Favorite No Favorites Selected
Go to XMFWildWeasel’s CAPS page

Boards Stats & Trivia

Old School Fool
Board Posts 12
Recs Received 19
People who have rec'd these posts 13
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board Inside Value: Interesting Stock
Very First Post Re: Boston Scientific (BSX) (6/15/2005)
Percentage of Posts Rec'd 66.67 %
Show XMFWildWeasel’s 10 Latest Posts